Cardiometabolic Disease, Hyperlipidemia
Conditions
Keywords
Telehealth, Cardiometabolic Disease, Hyperlipidemia
Brief summary
The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.
Detailed description
Efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. We can comprehend the influence of the combination of online and offline models on patients' clinical curative effect, medication compliance, medical cost, and satisfaction by analyzing the curative effect and finding a scientific basis for clinical practice and policy formation. As a result, the purpose of this study is to assess the curative effect of hyperlipidemia patients with other cardiometabolic disease using a telehealth integrated model, as well as to investigate the potential benefits and risks of this model in the management of cardiometabolic disease.
Interventions
PROCEDURETelehealth integrated care
Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
PROCEDUREConventional health care
Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
Sponsors
Peking University Third Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 85 Years
Inclusion criteria
* Age ≥ 16 years, and ≤ 85 years; * Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus; * Agreed to be enrolled in this study.
Exclusion criteria
* Undergone percutaneous coronary intervention within one year in our hospital; * Severe LV dysfunction, such as LV ejection fraction \< 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV; * Structural heart disease, or severe arrhythmia; * Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy; * could not complete at least one-year-followup.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes of compliance rate of target treatment for hyperlipidemia | 12 month after recuitment | difference of compliance rate of target treatment for hyperlipidemia between endpoint with baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes of glycosylated hemoglobin | 12 month after recuitment | difference of glycosylated hemoglobin between endpoint with baseline |
| changes of fasting glucose | 12 month after recuitment | difference of fasting glucose between endpoint with baseline |
| changes of LDL-c | 12 month after recuitment | difference of LDL-c between endpoint with baseline |
| changes of triglyceride | 12 month after recuitment | difference of triglyceride between endpoint with baseline |
| abnormal liver function | 12 month after recuitment | an increase above the 3-fold normal value for ALT or AST. |
| abnormal kidney function | 12 month after recuitment | an increase in creatinine of ≥ 30% |
| changes of blood pressure | 12 month after recuitment | difference of blood pressure（both systolic and diastolic blood pressure will be measured.） between endpoint with baseline |
| Cardiovascular death | 12 month | Death because of cardiovascular diseases and sudden death |
| medication adherence rate | 12 month | Difference of medication adherence between each group measured by Morisky Medication Adherence Scale-8 |
| patients satisfaction | 12 month | patients will be asked to rate their satisfaction score in Likert form with 1 being the most unsatisfactory and 5 being the most satisfactory on the overall experience, the medical diagnosis process, service attitude and physician's professionalism. |
| medical cost | 12 month | Health Economics on medical cost, transportation cost, accommodation cost, waiting time and lost work time |
| in person visit counts | 12 month after recuitment | total number of in person visits |
| telehealth visit counts | 12 month after recuitment | total number of telehealth visits |
| Rehospitalization | 12 month | Rehospitalization because of coronary heart disease, poor blood pressure control, and poor glycemic control |
Countries
China
Contacts
Primary ContactLequn Zhou, Dr
Backup ContactYipei Wang, Ph.D
Outcome results
None listed